Patients and Methods
All patients followed in a SFCE center and diagnosed with a SARS-CoV-2
infection who had undergone anti-cancer treatment in the past 6 months
ago were enrolled in the study. We also included all patients from SFCE
centers who underwent a hematopoietic stem-cell transplantation (HSCT)
for any reason and with immunosuppressive therapy either ongoing or
interrupted less than 6 months prior. Since SFCE centers may provide
care in children and adolescents as well as in young adults, there was
no limit of age to enroll patients in the study.
Diagnosis criteria for SARS-CoV-2 infection were as follows: (1)
biologically proven infection with positive polymerase chain reaction
(PCR) or positive specific positive IgM SARS-CoV-2 serology, (2)
clinical and radiological diagnosis with at least two (if any contact
with a suspected or confirmed COVID-19 case) or three (if no notion of
contact) clinical signs (comprising fever, cough, loss of smell, loss of
taste, myalgia, chest pain, dyspnea, respiratory distress syndrome,
rhinorrhea, diarrhea, headaches, asthenia and skin rash) and
computed-tomography(CT)-scan signs (ground glass opacities,
crazy-paving, linear condensations with a peripheral and/or bilateral
distribution) compatible with SARS-CoV-2 infection. All patients and
their families were informed of this study. The study was approved by
the ethics committee of the coordinating center (N°04/2020/ROU). This
study is registered in clinicaltrial.gov (NCT04433871).